人白血病细胞系筛选抗癌药物的可行性

The Feasibility for Screening Anticancerous Drug Using Human Leukemic Cell Lines

背景与目的 :探讨以人白血病细胞系筛选抗癌药物的可行性。 材料与方法 :应用活细胞计数法 ,3H_TdR及 3H_UR掺入 ,克隆分析法判断抗癌药物对肿癌细胞的杀伤能力。结果 :用人白血病细胞系K562和HL_60来检测对3种已知抗肿瘤药物(阿糖胞苷、柔红霉素、三尖杉酯碱)和一种新的药物MTB。在实验条件完全相同的条件下 ,同时用4种方法在不同药物浓度下存活分数曲线十分接近 ,其敏感范围在10 -2以内 ,克隆分析法检测敏感度可达10 -7水平。K562细胞存活分数高于HL_60细胞 ,与临床治疗结果相一致。结论 :采用人白血病细胞系为靶细胞进行抗癌药物的选择具有一定的优越性 ,不仅实验操作简便 ,而且与临床有较好的相关性。

BACKGROUND&AIM: To test the feasibility to use leukemic cell lines in the screening process for anˉticancerous drugs. MATERIAL AND METHODS: Human leukemic cell lines HL-60and K562were tested for their sensitivity to three known anticancerous drugs(Ara-c,DNR,Hom)and a new one(MTB).The drug sensitivity was assessed by four methods(survival cell count, 3 H-TdR incorporation, 3 H-UR incorporation and clone forming assay)and expressed in ED 50 . RESULTS: The curves of survival cell rate determined by the first three methods showed the sensitivity was well within the range of10 -2 ,approxi-mating to one another,while in the case of cloning method,the sensitivity was as high as10 -7 .Besides,the survival cell rate of K562was higher than that of HL-60. CONCLUSION: To use human leukemic cell lines as the target cell for anticancerous drug screening has the advantages that the laboratory procedures are relatively simple and the results are of better clinical significance.